Thomas Cummings
Overview
Explore the profile of Thomas Cummings including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
296
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bertran M, Walmsley R, Cummings T, Aramburu I, Benton D, Mora Molina R, et al.
Nat Commun
. 2024 Nov;
15(1):9746.
PMID: 39528459
Peptidylarginine deiminase IV (PADI4, PAD4) deregulation promotes the development of autoimmunity, cancer, atherosclerosis and age-related tissue fibrosis. PADI4 additionally mediates immune responses and cellular reprogramming, although the full extent of...
2.
Fetcko-Fayad K, Batich K, Reitman Z, Walsh K, Chamberlin G, Smith V, et al.
Brain Sci
. 2024 Feb;
14(2).
PMID: 38391718
Both glioblastoma (GBM) and dementia are devastating diseases with limited treatments that are usually not curative. Having clinically diagnosed dementia with an associated biopsy-proven etiology and a coexisting GBM diagnosis...
3.
Millrine D, Cummings T, Matthews S, Peter J, Magnussen H, Lange S, et al.
Cell Rep
. 2022 Aug;
40(5):111168.
PMID: 35926457
An essential first step in the post-translational modification of proteins with UFM1, UFMylation, is the proteolytic cleavage of pro-UFM1 to expose a C-terminal glycine. Of the two UFM1-specific proteases (UFSPs)...
4.
Jackson D, Parker J, Cummings T
J Med Case Rep
. 2021 Apr;
15(1):173.
PMID: 33812374
Background: Central hyperthyroidism is a rare form of hyperthyroidism caused by thyrotrope pituitary adenomas. It is characterized by elevated thyroid-stimulating hormone alongside high thyroxine and triiodothyronine. Goiter is the most...
5.
Wolf L, Cummings T, Muller K, Reppke M, Volkmar M, Weuster-Botz D
Eng Life Sci
. 2021 Mar;
21(3-4):115-125.
PMID: 33716611
Batch growth and β-carotene production of CCAP19/18 was investigated in flat-plate gas-lift photobioreactors with a light path of 2 cm, operated in physically simulated outdoor conditions. CCAP19/18 showed robust growth...
6.
Evans M, Butt M, Belanger P, Cummings T, Gremminger J, Zorbas M
Auton Neurosci
. 2019 Mar;
218:51-53.
PMID: 30890348
Tanezumab, a humanized monoclonal anti-NGF antibody, has demonstrated efficacy and safety profiles in Phase III clinical trials of chronic pain. In a 24-week study in non-human primates, morphological observations of...
7.
Harrison W, Pittman P, Cummings T
Saudi J Ophthalmol
. 2018 May;
32(1):90-91.
PMID: 29755281
No abstract available.
8.
Harrison W, Pittman P, Cummings T
Saudi J Ophthalmol
. 2018 May;
32(1):13-16.
PMID: 29755265
Pleomorphic adenoma (benign mixed tumor) is the most common epithelial neoplasm of the lacrimal gland. It is usually a slow growing, well-circumscribed, mass that is identical to its salivary gland...
9.
Belanger P, Butler P, Butt M, Bhatt S, Foote S, Shelton D, et al.
Toxicol Sci
. 2017 May;
158(2):319-333.
PMID: 28525647
Tanezumab, a humanized monoclonal antibody against nerve growth factor is in development for treatment of chronic pain. Three nonclinical studies assessed effects of clinically relevant and supratherapeutic doses of tanezumab...
10.
Bowman C, Evans M, Cummings T, Oneda S, Butt M, Hurst S, et al.
Reprod Toxicol
. 2014 Dec;
53:105-18.
PMID: 25461901
Two intravenous studies with tanezumab, an anti-nerve growth factor monoclonal antibody, were conducted in pregnant cynomolgus monkeys to assess potential effects on pregnancy and pre- and postnatal development. Study 1...